2018
The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, Walensky RP, Freedberg KA. The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India. Journal Of The International AIDS Society 2018, 21: e25085. PMID: 29603882, PMCID: PMC5878415, DOI: 10.1002/jia2.25085.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careAntiretroviral therapyTenofovir disoproxil fumarateHIV infectionRecent guidelinesFirst-line antiretroviral therapyFirst-line HIV treatmentLifetime incremental cost-effectiveness ratioART-naive patientsDolutegravir-based regimenDTG-based regimenFirst-line treatmentClinical trial dataCost-effectiveness ratioLifetime care costsInitial therapyVirologic suppressionCD4 countHIV diseaseRegimen costsDisoproxil fumarateHIV treatmentAIDS complicationsCare costs
2001
Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus
Paltiel A, Goldie S, Losina E, Weinstein M, Seage G, Kimmel A, Zhang H, Freedberg K. Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001, 32: 783-793. PMID: 11229847, DOI: 10.1086/319223.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiviral AgentsChemopreventionCost-Benefit AnalysisCytomegalovirusCytomegalovirus InfectionsGanciclovirHIV InfectionsHumansModels, BiologicalPolymerase Chain ReactionPredictive Value of TestsQuality-Adjusted Life YearsSensitivity and SpecificityValganciclovirConceptsHuman immunodeficiency virusDuration of survivalPreemptive therapyCMV casesImmunodeficiency virusCMV polymerase chain reactionEnd-stage HIV diseaseUpcoming trialsCMV preemptive therapySalvage antiretroviral therapyCells/microLClinical trial dataCMV prophylaxisAntiretroviral therapyHIV diseaseComplication rateEfficacy assumptionsPolymerase chain reactionDisease progressionClinical uncertaintyDrug effectsPatientsTrial dataTherapyChain reaction